Gilead Sciences, Inc.

30 Archived Projects

Title Investigator Start End
Gilead Drug Donation for Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa Martin
Atripla Adherence and Resistance Relationships [I] Deeks
Treating HIV-infected Elite Controllers as a Model of HIV Remission Deeks
Gilead GS-US-236-0102 Luetkemeyer
Protocol GS-US-334-0139 An Expanded Access Phase 2 Study of Sofosbuvir and Ribavarin with or without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive Recurrent Hepatitis C Infection
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) Luetkemeyer
Gilead HCAT Support-SOMA Project Dilley
Tenofovir Kidney Toxicity Study
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti Luetkemeyer
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects Luetkemeyer
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection Luetkemeyer
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts Jain
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Luetkemeyer
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Luetkemeyer
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection Khalili
Patients' HBV Knowledge, Attitudes, Barriers to HBV Care and HBV Treatment Khalili
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease Khalili
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts Jain
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Khalili
Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B Khalili
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers Deeks
Grant to support UCSF Global Health Impact Fund Feachem
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed Khalili
Global Leaders for Universal Health Coverage (UHC) [GL-UHC] Goosby
Sustainable East Africa Research in Community Health Havlir
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection Rosenthal
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection Rosenthal
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co Luetkemeyer
The No One Waits (NOW) Study: Acceptability, feasibility, and effectiveness of a community based on-site point-of-diagnosis HCV treatment study Morris
Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection Rosenthal